期刊文献+

玻璃体积血病因及预后影响因素分析 被引量:6

Study on the causes of vitreous hemorrhage and influence factors on its prognosis
下载PDF
导出
摘要 目的研究玻璃体积血的常见病因及可能影响预后的因素。方法收集80例(80只眼)玻璃体积血患者的发病原因及各项因素,对结果进行统计研究及分析。结果糖尿病视网膜病变占46.25%,视网膜静脉阻塞占31.25%。治疗前视力与治疗后视力有弱相关性(相关系数r=0.378,P<0.05)。结论糖尿病视网膜病变、视网膜静脉阻塞是玻璃体积血的主要病因,治疗前视力是影响玻璃体积血预后的因素之一。 Objective To study the causes of vitreous hemorrhage and the possible factors affecting its outcome. Methods The clinical data of causes and various factors in 80 patients with vitreous hemorrhage (80 eyes) were collected, then their results were statistically analyzed. Results The diabetic retinopathy was accounted for 46. 25 % , and retinal vein occlusion was accounted for 31.25%. There was slight correlation between visual acuity before and after the treatment (correlation coefficient r = 0. 378 , P 〈 0. 05 ) . Conclusion The main causes of vitreous hemorrhage are diabetic retinopathy and occlusion of retinal vein, and the visual acuity before treatment is one of the factors affecting the prognosis of vitreous hemorrhage.
作者 许超 接传红
出处 《临床和实验医学杂志》 2016年第17期1739-1741,共3页 Journal of Clinical and Experimental Medicine
关键词 玻璃体积血 病因 预后 影响因素 Vitreous Hemorrhage Causes Prognosis Influencing Factors
  • 相关文献

参考文献11

二级参考文献45

  • 1王建民,马景学,叶存喜,黄灵欣,盛孟怡.非外伤性玻璃体大量积血的病因分析[J].中国实用眼科杂志,2006,24(1):100-103. 被引量:17
  • 2王树林,金学民.糖尿病鼠视网膜细胞间黏附分子-1的表达与血视网膜屏障破坏的关系及曲安奈德的治疗作用[J].中华眼底病杂志,2006,22(1):24-27. 被引量:8
  • 3姜燕荣,王凯,黎晓新.曲安奈德玻璃体腔注射治疗视网膜静脉阻塞继发黄斑水肿的疗效观察[J].眼科研究,2006,24(6):639-642. 被引量:18
  • 4赵明威 张承芬 等.糖尿病的玻璃体改变.眼底病学[M].北京:人民卫生出版社,1998.34-36.
  • 5Flynn HW Jr, Chew EY, Simons BD, et al. Pars plana vitrectomy in the Early Treatment Diabetic Retinopathy Study: ETDRS report number 17. The Early Treatment DiabeticRetinopathy Study Research Group. Ophthalmology, 1992,99: 1351-1357.
  • 6The CATT Research Group. Ranibizumab and bevacizumab for neovaseular age-related macular degeneration. N Engl J Med, 2011,364:1897-1908.
  • 7Chen E, Park CH. Use of intravitreal bevacizumab as a preoperative adjunct for tractional retinal detachment repair in severe proliferative diabetic retinopathy. Retina, 2006,26: 699- 700.
  • 8Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med, 2009,151 : 264-269, W64.
  • 9Jadad AR, Moore RA, Carroll D, et aL Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials, 1996,17 : 1-12.
  • 10Two-year course of visual acuity in retinopathy with conventional Retinopathy Vitrectomy Study Ophthalmology, 1985,92 .. 492-502.

共引文献61

同被引文献38

引证文献6

二级引证文献22

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部